WO2010139180A1 - 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 - Google Patents
作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 Download PDFInfo
- Publication number
- WO2010139180A1 WO2010139180A1 PCT/CN2010/000272 CN2010000272W WO2010139180A1 WO 2010139180 A1 WO2010139180 A1 WO 2010139180A1 CN 2010000272 W CN2010000272 W CN 2010000272W WO 2010139180 A1 WO2010139180 A1 WO 2010139180A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- diseases
- hydrogen
- trifluoromethyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
- C07D215/28—Alcohols; Ethers thereof with halogen atoms or nitro radicals in positions 5, 6 or 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI1011994A BRPI1011994B8 (pt) | 2009-06-04 | 2010-03-05 | derivados de naftaleno carboxamida como inibidores de proteína quinase e histona desacetilase, métodos de preparação e usos |
KR1020147000095A KR20140014313A (ko) | 2009-06-04 | 2010-03-05 | 단백질 키나제 및 히스톤 디아세틸라제의 억제제로서 나프탈렌 카르복스아미드 유도체, 그 제조 방법 및 용도 |
MX2011012752A MX2011012752A (es) | 2009-06-04 | 2010-03-05 | Derivados de naftalenocarboxamida como inhibidores de proteina quinasa y de histona desacetilasa, procedimientos de preparacion y usos de los mismos. |
KR1020117030659A KR101421786B1 (ko) | 2009-06-04 | 2010-03-05 | 단백질 키나제 및 히스톤 디아세틸라제의 억제제로서 나프탈렌 카르복스아미드 유도체, 그 제조 방법 및 용도 |
SI201030695T SI2439195T1 (sl) | 2009-06-04 | 2010-03-05 | Derivati naftalen karboksamida kot inhibitorji protein kinaze in histon deacetilaze, pripravljalni postopki in njihova uporaba |
CA2763822A CA2763822C (en) | 2009-06-04 | 2010-03-05 | Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof |
EP10782884.0A EP2439195B1 (en) | 2009-06-04 | 2010-03-05 | Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof |
JP2012513451A JP5484568B2 (ja) | 2009-06-04 | 2010-03-05 | プロテインキナーゼおよびヒストンデアセチラーゼの阻害剤としてのナフタレンカルボキサミド誘導体、その製造方法および用途 |
ES10782884.0T ES2509615T3 (es) | 2009-06-04 | 2010-03-05 | Derivados de naftaleno carboxamida como inhibidores de proteína cinasa e histona desacetilasa, procedimientos de preparación y usos de los mismos |
RU2011152113/04A RU2497809C2 (ru) | 2009-06-04 | 2010-03-05 | Производные нафталинкарбоксамида в качестве ингибиторов протеинкиназы и гистондеацетилазы, способы их получения и применение |
UAA201115118A UA103092C2 (ru) | 2009-06-04 | 2010-03-05 | Производные нафталинкарбоксамида как ингибиторы протеинкиназы и гистондеацетилазы, способ их получения и применения |
DK10782884.0T DK2439195T3 (da) | 2009-06-04 | 2010-03-05 | Naftalenkarboxamidderivater som proteinkinasehæmmere og histondeacetlylase, fremstillingsmetoder samt anvendelser deraf |
PL10782884T PL2439195T3 (pl) | 2009-06-04 | 2010-03-05 | Pochodne naftalenokarboksyamidu jako inhibitory kinazy białkowej i deacetylazy histonowej, sposoby ich wytwarzania oraz ich zastosowania |
AU2010256246A AU2010256246B9 (en) | 2009-06-04 | 2010-03-05 | Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase, preparation methods and uses thereof |
ZA2011/09030A ZA201109030B (en) | 2009-06-04 | 2011-12-08 | Naphthalene carboxamide derivatives as inhibitors of protein kinase and histone deacetylase,preparation methods and uses thereof |
HRP20140717AT HRP20140717T1 (hr) | 2009-06-04 | 2014-07-25 | Derivati naftalen karboksamida kao inhibitori protein kinaze i histon deacetilaze, postupci njihove pripreme i njihove uporabe |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910143978 | 2009-06-04 | ||
CN200910143978.2 | 2009-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010139180A1 true WO2010139180A1 (zh) | 2010-12-09 |
WO2010139180A8 WO2010139180A8 (zh) | 2012-01-05 |
Family
ID=43261686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/000272 WO2010139180A1 (zh) | 2009-06-04 | 2010-03-05 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2439195B1 (zh) |
JP (1) | JP5484568B2 (zh) |
KR (2) | KR101421786B1 (zh) |
CN (1) | CN101906076B (zh) |
AU (1) | AU2010256246B9 (zh) |
BR (1) | BRPI1011994B8 (zh) |
CA (1) | CA2763822C (zh) |
DK (1) | DK2439195T3 (zh) |
ES (1) | ES2509615T3 (zh) |
HR (1) | HRP20140717T1 (zh) |
MX (1) | MX2011012752A (zh) |
PL (1) | PL2439195T3 (zh) |
PT (1) | PT2439195E (zh) |
RU (1) | RU2497809C2 (zh) |
SI (1) | SI2439195T1 (zh) |
UA (1) | UA103092C2 (zh) |
WO (1) | WO2010139180A1 (zh) |
ZA (1) | ZA201109030B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103351336A (zh) * | 2013-06-28 | 2013-10-16 | 华侨大学 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘甲酰胺衍生物及其制备方法 |
CN103896836A (zh) * | 2014-03-20 | 2014-07-02 | 华侨大学 | N-苯基-6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺及其制备方法 |
CN103923004A (zh) * | 2014-04-04 | 2014-07-16 | 华侨大学 | 一种萘甲酰胺衍生物及其制备和应用 |
CN104030980A (zh) * | 2014-06-10 | 2014-09-10 | 华侨大学 | N-(3-甲氧基-4-氯苯基)-4-[(7-氯-4-喹啉)氨基]苯甲酰胺及其制备和应用 |
WO2018187894A1 (zh) * | 2017-04-10 | 2018-10-18 | 师健友 | 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物 |
RU2784869C1 (ru) * | 2019-03-25 | 2022-11-30 | Шэньчжэнь Чипскрин Байосайенсиз Ко., Лтд. | Чиаураниб для лечения мелкоклеточного рака легкого |
WO2022247844A1 (zh) * | 2021-05-26 | 2022-12-01 | 深圳微芯生物科技股份有限公司 | 包含蛋白激酶抑制剂的药物组合物及其医药用途 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
CN102260210B (zh) * | 2011-05-30 | 2012-06-27 | 王立强 | 蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物的制备方法 |
CN102603627B (zh) * | 2011-05-31 | 2013-02-06 | 王立强 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物及其制备方法 |
CN102850236B (zh) * | 2011-06-27 | 2016-05-18 | 国药一心制药有限公司 | 新型苯甲酰胺类组蛋白去乙酰化酶抑制剂及其应用 |
CN103420923B (zh) * | 2012-05-18 | 2015-08-19 | 国药一心制药有限公司 | 4-氨基喹唑啉异羟肟酸类化合物及作为抗肿瘤药物应用 |
CN103288728A (zh) * | 2013-05-17 | 2013-09-11 | 华侨大学 | 一种萘甲酰胺衍生物、其制备方法以及应用 |
CN103432077A (zh) * | 2013-08-21 | 2013-12-11 | 北京淦航医药科技有限公司 | 西达苯胺固体分散制剂 |
CN104418867B (zh) * | 2013-08-26 | 2016-12-28 | 上海汇伦生命科技有限公司 | 作为PI3K/mTOR抑制剂的化合物,其制备方法和用途 |
CN103724260A (zh) * | 2013-12-18 | 2014-04-16 | 华侨大学 | 一种苯甲酰胺衍生物及其制备方法和应用 |
CN104860885B (zh) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | 萘酰胺类化合物、其制备方法和用途 |
CN105399685B (zh) * | 2014-09-16 | 2018-05-22 | 深圳微芯生物科技有限责任公司 | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 |
CN104447534A (zh) * | 2014-12-04 | 2015-03-25 | 厦门大学 | 6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺类衍生物及其制备方法和用途 |
CN107868044B (zh) | 2016-09-27 | 2020-10-16 | 深圳微芯生物科技股份有限公司 | 一种非溶剂化晶体及其制备方法与应用 |
CN109985039A (zh) * | 2017-12-29 | 2019-07-09 | 深圳微芯生物科技股份有限公司 | 用于治疗白血病的联合用药物及其在制备用于治疗急性髓性白血病的药物中的用途 |
CN114681455A (zh) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途 |
CN109908143B (zh) * | 2018-12-18 | 2021-11-19 | 厦门大学附属第一医院 | 西奥罗尼在制备治疗急性髓系白血病药物的新用途 |
TW202332445A (zh) * | 2019-03-25 | 2023-08-16 | 大陸商深圳微芯生物科技股份有限公司 | 西奧羅尼用於小細胞肺癌的治療 |
CN113440615A (zh) * | 2020-03-24 | 2021-09-28 | 深圳微芯生物科技股份有限公司 | 包含蛋白激酶抑制剂和化疗药物的药物组合物及其用途 |
CN114246864A (zh) * | 2020-09-23 | 2022-03-29 | 上海润石医药科技有限公司 | Csf1r激酶抑制剂及其用途 |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847992A1 (en) | 1996-09-30 | 1998-06-17 | Mitsui Chemicals, Inc. | Benzamide derivatives, useful as cell differentiation inducers |
WO2001018171A2 (en) | 1999-09-08 | 2001-03-15 | Sloan-Kettering Institute For Cancer Research | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
WO2001070675A2 (en) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2002026696A1 (en) | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
WO2005021553A1 (en) * | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
US7041687B2 (en) | 2002-01-25 | 2006-05-09 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
US7098330B2 (en) | 2000-09-15 | 2006-08-29 | Vertex Pharmaceuticals Incorporated | Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors |
US7125905B2 (en) | 2000-02-15 | 2006-10-24 | Agouron Pharmaceuticals, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
US7132533B2 (en) | 2003-01-09 | 2006-11-07 | Agouron Pharmaceuticals, Inc. | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy |
US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
US7157476B2 (en) | 2003-08-20 | 2007-01-02 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
US7166597B2 (en) | 2000-08-22 | 2007-01-23 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
US7179910B2 (en) | 2001-02-15 | 2007-02-20 | Agouron Pharmaceuticals, Inc. | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors |
US7189721B2 (en) | 1997-05-07 | 2007-03-13 | Sugen Inc. | Bicyclic protein kinase inhibitors |
CN1933839A (zh) * | 2004-01-23 | 2007-03-21 | 安进公司 | 化合物和使用方法 |
US7214700B2 (en) | 2000-05-02 | 2007-05-08 | Sugen Inc. | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4405602B2 (ja) * | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
EP1429765A2 (en) * | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
TWI319387B (en) * | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
EP2060565A1 (en) * | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
-
2009
- 2009-11-24 CN CN2009102238615A patent/CN101906076B/zh active Active
-
2010
- 2010-03-05 ES ES10782884.0T patent/ES2509615T3/es active Active
- 2010-03-05 BR BRPI1011994A patent/BRPI1011994B8/pt active IP Right Grant
- 2010-03-05 DK DK10782884.0T patent/DK2439195T3/da active
- 2010-03-05 WO PCT/CN2010/000272 patent/WO2010139180A1/zh active Application Filing
- 2010-03-05 CA CA2763822A patent/CA2763822C/en active Active
- 2010-03-05 SI SI201030695T patent/SI2439195T1/sl unknown
- 2010-03-05 KR KR1020117030659A patent/KR101421786B1/ko active IP Right Grant
- 2010-03-05 KR KR1020147000095A patent/KR20140014313A/ko not_active Application Discontinuation
- 2010-03-05 JP JP2012513451A patent/JP5484568B2/ja active Active
- 2010-03-05 PL PL10782884T patent/PL2439195T3/pl unknown
- 2010-03-05 AU AU2010256246A patent/AU2010256246B9/en active Active
- 2010-03-05 MX MX2011012752A patent/MX2011012752A/es active IP Right Grant
- 2010-03-05 UA UAA201115118A patent/UA103092C2/ru unknown
- 2010-03-05 PT PT107828840T patent/PT2439195E/pt unknown
- 2010-03-05 RU RU2011152113/04A patent/RU2497809C2/ru active
- 2010-03-05 EP EP10782884.0A patent/EP2439195B1/en active Active
-
2011
- 2011-12-08 ZA ZA2011/09030A patent/ZA201109030B/en unknown
-
2014
- 2014-07-25 HR HRP20140717AT patent/HRP20140717T1/hr unknown
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847992A1 (en) | 1996-09-30 | 1998-06-17 | Mitsui Chemicals, Inc. | Benzamide derivatives, useful as cell differentiation inducers |
US7189721B2 (en) | 1997-05-07 | 2007-03-13 | Sugen Inc. | Bicyclic protein kinase inhibitors |
WO2001018171A2 (en) | 1999-09-08 | 2001-03-15 | Sloan-Kettering Institute For Cancer Research | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof |
US7125905B2 (en) | 2000-02-15 | 2006-10-24 | Agouron Pharmaceuticals, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2001070675A2 (en) | 2000-03-24 | 2001-09-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US7214700B2 (en) | 2000-05-02 | 2007-05-08 | Sugen Inc. | (2-Oxindol-3-ylidenyl) acetic acid derivatives and their use as protein kinase inhibitors |
US7166597B2 (en) | 2000-08-22 | 2007-01-23 | Glaxo Group Limited | Fused pyrazole derivatives being protein kinase inhibitors |
US7098330B2 (en) | 2000-09-15 | 2006-08-29 | Vertex Pharmaceuticals Incorporated | Pyrazolylamine substituted quinazoline compounds useful as protein kinase inhibitors |
US7115739B2 (en) | 2000-09-15 | 2006-10-03 | Vertex Pharmaceuticals Incorporated | Triazole compounds useful as protein kinase inhibitors |
WO2002026696A1 (en) | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
US20020103192A1 (en) | 2000-10-26 | 2002-08-01 | Curtin Michael L. | Inhibitors of histone deacetylase |
US7179910B2 (en) | 2001-02-15 | 2007-02-20 | Agouron Pharmaceuticals, Inc. | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors |
US7041687B2 (en) | 2002-01-25 | 2006-05-09 | Vertex Pharmaceuticals Incorporated | Indazole compounds useful as protein kinase inhibitors |
US7132533B2 (en) | 2003-01-09 | 2006-11-07 | Agouron Pharmaceuticals, Inc. | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy |
US7151096B2 (en) | 2003-03-05 | 2006-12-19 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
US7157476B2 (en) | 2003-08-20 | 2007-01-02 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
WO2005021553A1 (en) * | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
CN1933839A (zh) * | 2004-01-23 | 2007-03-21 | 安进公司 | 化合物和使用方法 |
Non-Patent Citations (37)
Title |
---|
ARTEAGA, C-L., CURR. OPIN. ONCOL., vol. 6, 2001, pages 491 - 498 |
AVILA AM ET AL., J CLINIC INVESTIGATION, vol. 117, no. 3, 2007, pages 659 - 71 |
BARTL. S., MOL. CELL BIOL., vol. 17, 1997, pages 5033 - 5043 |
DE BORE J, TISSUE ENG., vol. 12, no. 10, 2006, pages 2927 - 37 |
DOKMANOVIC, M., J. CELL BIOCHENM., vol. 96, 2005, pages 293 - 304 |
DU, JUAN ET AL.: "Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, vol. 27, 5 November 2008 (2008-11-05), pages 642 - 654, XP025815659 * |
GIALITAKIS M ET AL., NUCLEIC ACIDS RES., vol. 34, no. 1, 2007, pages 765 - 72 |
GLAROS S ET AL., ONCOGENE, 4 June 2007 (2007-06-04) |
GLASER, K-B., BIOCHEM. BIOPHYS. RES. COMM., vol. 310, 2003, pages 529 - 536 |
GRIGNANI, F., NATURE, vol. 391, 1998, pages 815 - 818 |
GRUNSTEIN, M., NATURE, vol. 389, 1997, pages 349 - 352 |
HAQ ET AL., J. CELL BIOL., vol. 151, 2000, pages 117 |
HARMANGE, JEAN-CHRISTOPHE ET AL.: "Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.", J. MED. CHEM., vol. 51, 2008, pages 1649 - 1667, XP002668409 * |
HEALY, A., J. IMMUNOL., vol. 177, 2006, pages 1886 - 1893 |
HERMAN D ET AL., NATURE CHEMICAL BIOLOGY, vol. 2, no. 10, 2006, pages 551 - 8 |
KIM, J. ET AL., J. CLIN. INVEST., vol. 114, 2004, pages 823 - 827 |
KIMURA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 13766 - 13771 |
LAGGER, G., EMBO J., vol. 21, 2002, pages 2672 - 2681 |
LANGLEY B ET AL., CURRENT DRUG TARGETS-CNS & NEUROLOGICAL DISORDERS, vol. 4, 2005, pages 41 - 50 |
LIN, R-J., NATURE, vol. 391, 1998, pages 811 - 814 |
MAI, A ET AL., INT J. BIOCHEM CELL BIO. |
MARKS, P-A., NATURE REVIEWS CANCER, vol. 1, 2001, pages 194 |
MENDELSOHN, J., CLIN. CAN. RES., vol. 3, 1997, pages 2707 - 2707 |
MONIA ET AL., NAT. MED., vol. 2, 1996, pages 668 - 675 |
PARIKH, A-A., HEMATOL. ONCOL. CLIN. N. AM., vol. 18, 2004, pages 951 - 971 |
PETIT, A-M. ET AL., AM. J. PATHOL., vol. 151, 1997, pages 1523 - 1530 |
RUIJTER, A-J-M., BIOCHEM. J., vol. 370, 2003, pages 737 - 749 |
SAKUMA, T, INT. J. ONCOL., vol. 29, 2006, pages 117 - 124 |
SALEK-ARDAKANI, S. ET AL., J. IMMUNOL., vol. 175, 2005, pages 7635 - 7641 |
SCHUMACHER ET AL., J. CELL BIOL., vol. 143, 1998, pages 1635 - 1646 |
See also references of EP2439195A4 |
TAN, S-L., J. IMMUNOL., vol. 176, 2006, pages 2872 - 2879 |
TRIVEDI, C-M., NAT. MED, vol. 13, 2007, pages 324 - 331 |
VINCENT A. ET AL., ONCOGENE, 30 April 2007 (2007-04-30) |
WIKSTRAND, C-J. ET AL., J NATL CANCER INST., vol. 90, 1998, pages 799 - 800 |
WIKSTRAND, C-J., J NATL CANCER INST., vol. 90, 1998, pages 799 - 800 |
WILSON, A-J., J BIOL. CHEM., vol. 281, 2006, pages 13548 - 13558 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103351336A (zh) * | 2013-06-28 | 2013-10-16 | 华侨大学 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘甲酰胺衍生物及其制备方法 |
CN103896836A (zh) * | 2014-03-20 | 2014-07-02 | 华侨大学 | N-苯基-6-[(7-氯喹啉-4-氧基)酚醚]-2-萘甲酰胺及其制备方法 |
CN103923004A (zh) * | 2014-04-04 | 2014-07-16 | 华侨大学 | 一种萘甲酰胺衍生物及其制备和应用 |
CN104030980A (zh) * | 2014-06-10 | 2014-09-10 | 华侨大学 | N-(3-甲氧基-4-氯苯基)-4-[(7-氯-4-喹啉)氨基]苯甲酰胺及其制备和应用 |
WO2018187894A1 (zh) * | 2017-04-10 | 2018-10-18 | 师健友 | 一种用于治疗肿瘤疾病以及具有抗菌、抗病毒和抗炎作用的药物 |
RU2784869C1 (ru) * | 2019-03-25 | 2022-11-30 | Шэньчжэнь Чипскрин Байосайенсиз Ко., Лтд. | Чиаураниб для лечения мелкоклеточного рака легкого |
WO2022247844A1 (zh) * | 2021-05-26 | 2022-12-01 | 深圳微芯生物科技股份有限公司 | 包含蛋白激酶抑制剂的药物组合物及其医药用途 |
Also Published As
Publication number | Publication date |
---|---|
KR101421786B1 (ko) | 2014-07-22 |
JP5484568B2 (ja) | 2014-05-07 |
ZA201109030B (en) | 2013-02-27 |
BRPI1011994A2 (pt) | 2016-05-10 |
RU2497809C2 (ru) | 2013-11-10 |
DK2439195T3 (da) | 2014-09-22 |
BRPI1011994B1 (pt) | 2020-04-07 |
KR20140014313A (ko) | 2014-02-05 |
EP2439195A4 (en) | 2012-10-31 |
PT2439195E (pt) | 2014-09-10 |
UA103092C2 (ru) | 2013-09-10 |
EP2439195A1 (en) | 2012-04-11 |
BRPI1011994B8 (pt) | 2021-05-25 |
CN101906076B (zh) | 2013-03-13 |
WO2010139180A8 (zh) | 2012-01-05 |
PL2439195T3 (pl) | 2015-02-27 |
SI2439195T1 (sl) | 2014-12-31 |
AU2010256246B2 (en) | 2013-04-11 |
AU2010256246A1 (en) | 2012-01-12 |
KR20120016659A (ko) | 2012-02-24 |
CA2763822C (en) | 2014-12-09 |
JP2012528800A (ja) | 2012-11-15 |
CA2763822A1 (en) | 2010-12-09 |
HRP20140717T1 (hr) | 2014-11-21 |
ES2509615T3 (es) | 2014-10-17 |
AU2010256246B9 (en) | 2014-01-30 |
CN101906076A (zh) | 2010-12-08 |
EP2439195B1 (en) | 2014-07-16 |
MX2011012752A (es) | 2012-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010139180A1 (zh) | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 | |
US8211901B2 (en) | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | |
WO2017101803A1 (zh) | 一种新型egfr和alk激酶的双重抑制剂 | |
CN107531633B (zh) | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 | |
US9353062B2 (en) | Substituted quinolines as bruton's tyrosine kinases inhibitors | |
CN111051300B (zh) | 作为组蛋白脱乙酰基酶1和/或2(hdac1-2)的选择性抑制剂的新杂芳基酰胺衍生物 | |
JPWO2006104161A1 (ja) | c−Met自己リン酸化阻害作用を有するチエノピリジン誘導体、キノリン誘導体、およびキナゾリン誘導体 | |
JP6609308B2 (ja) | キナーゼ阻害剤としての置換マクロサイクル | |
JP6916562B2 (ja) | 化合物、その薬学的に許容される塩、溶媒和物、立体異性体及び互変異性体、並びに薬物組成物、過剰増殖性障害治療剤、過剰増殖性障害予防剤、薬物、癌治療剤、癌予防剤、及びキナーゼシグナル伝達調節剤 | |
JP7345901B2 (ja) | キナーゼ阻害剤として有用な置換大員環類 | |
CN110563697A (zh) | 2-吡啶甲酰胺类化合物的制备及应用 | |
Mularski et al. | The p53 stabilizing agent CP-31398 and multi-kinase inhibitors. Designing, synthesizing and screening of styrylquinazoline series | |
WO2020221006A1 (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
CN107151233B (zh) | 含腙的嘧啶类衍生物及其用途 | |
CN107311933B (zh) | 一类苯并咪唑衍生物,及其制备方法和用途 | |
WO2009014941A1 (en) | 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | |
US20230000876A1 (en) | Treating cancers with a cyclin-dependent kinase inhibitor | |
US11801243B2 (en) | Bromodomain inhibitors for androgen receptor-driven cancers | |
US8158656B2 (en) | 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | |
WO2014190872A1 (zh) | 一种含硒化合物及其医药用途 | |
JP2011520891A (ja) | 強力かつ選択的なヒストン脱アセチル化酵素阻害剤としての6−アミノニコチンアミド誘導体 | |
Deng et al. | Design, Synthesis and Biological Evaluation of 5-Amino-1h-Pyrazole-4-Carboxamide Derivatives as Pan-Fgfr Covalent Inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10782884 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2763822 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012513451 Country of ref document: JP Ref document number: MX/A/2011/012752 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010256246 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010782884 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201115118 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 20117030659 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011152113 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010256246 Country of ref document: AU Date of ref document: 20100305 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1011994 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1011994 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111130 |